Supreme Court Case Could Raise Generic Drug Costs

The Supreme Court case Hikma v. Amarin could raise prescription drug costs by discouraging "skinny labeling," which lets generic drugs reach market faster. A ruling favoring brand-name makers may prolong monopolies, delaying cheaper generics and increasing patient expenses.